
MacroGenics axes ADC drug following Phase II failure in prostate cancer
MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study in prostate cancer. The Rockville, Maryland-based biotech said trials of vobramitamab duocarmazine (vobra duo) would be culled after the …